logo

The phase-3 trials of Covaxin ensure unparalleled safety against the Covid-19 virus with: 93% efficacy against severe Covid-19 disease, reducing hospitalizations; 78% efficacy against mild, moderate, and severe Covid-19 disease

Leave Your Comment

 

 

Top